Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive international career in the biopharmaceutical industry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced R&D leader in immune-oncology (IO). Previously, participated in preclinical development of CD28 biologic modulators for inflammatory conditions, small molecule tyrosine kinase inhibitors and fully human antibodies for advanced solid tumors at Leadartis. He advanced the company from start to capitalize on the immuno-oncology (IO) market. Evaluated and repositioned the platform technology to create IO bispecific antibody dominance and created a proprietary next generation product…
Read More“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”- A brief discussion with Juan Perez Villar, CEO, LeadArtis.
